Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Acumen Pharmaceuticals Inc(ABOS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABOS
10/01/2026: ABOS (1-star) is currently NOT-A-BUY. Pass it for now.
Acumen Pharmaceuticals is a clinical-stage biotechnology company developing sabirnetug (ACU193), a novel antibody targeting toxic amyloid beta oligomers for Alzheimer's disease. Its core strength lies in a unique scientific approach that potentially improves efficacy over broader amyloid-clearing agents. The company’s primary investment story is binary: the success or failure of its lead candidate in clinical trials. Key risks include significant competition from well-capitalized firms and the high probability of clinical development setbacks. This stock is best suited for risk-tolerant investors looking for biotech exposure, and shareholders should monitor clinical data readouts and potential partnership announcements as key indicators of development progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential dependent entirely on clinical trial success, which carries binary risk. |
| Momentum investor | Mixed fit | Stock price movement is often driven by clinical updates and industry news rather than fundamental momentum. |
| Value investor | Weak fit | There are no current earnings or traditional value metrics to support a value-based investment thesis. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into research. |
| Low-risk investor | Weak fit | The high volatility and clinical risk inherent in biotech development are inappropriate for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are susceptible to massive price swings based on trial results and regulatory news. |
| Valuation risk | High | Without commercial products, valuations are speculative and difficult to ground in traditional financial ratios. |
| Competition risk (Major Pharma) | High | The company competes against much larger players with deeper pockets and established distribution networks. |
| Business quality | Medium | The business relies on a niche, high-potential science, but remains early-stage and unproven commercially. |
| Dividend income | Low / none | Investors seeking income will not find it here. |
| Execution risk | High | The inability to successfully navigate clinical trials or secure regulatory approval would be devastating to shareholder value. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -63.28% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/01/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.54M USD | Price to earnings Ratio - | 1Y Target Price 7.6 |
Price to earnings Ratio - | 1Y Target Price 7.6 | ||
Volume (30-day avg) 478.6K shares | Beta 0.38 | 52 Weeks Range 1.50 - 3.60 | Updated Date 10/01/2026 |
52 Weeks Range 1.50 - 3.60 | Updated Date 10/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical trial activities for sabirnetug (ACU193). | The company is currently burning cash to develop a drug and has no commercial revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 88.14M | Price to Sales(TTM) 538.78 |
Enterprise Value 88.14M | Price to Sales(TTM) 538.78 | ||
Enterprise Value to Revenue 24.48 | Enterprise Value to EBITDA -0.6 | Shares Outstanding 72.32M | Shares Floating 37.05M |
Shares Outstanding 72.32M | Shares Floating 37.05M | ||
Percent Insiders 6.79 | Percent Institutions 66.59 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Acumen Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Newton, MA, United States | ||
IPO Launch date 2021-07-01 | CEO & Director Mr. Daniel J. O'Connell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://acumenpharm.com |
Full time employees 60 | Website https://acumenpharm.com | ||
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.